A poster from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) conference held in Chicago, Illinois presented results of a clinical trial for patients with alopecia areata (AA). The trial used rilecitinib and showed promising results in patients with AA after most patients achieved significant hair regrowth following 15 months of treatment.
Different Janus kinase (JAK) inhibitors underwent an evaluation for severe alopecia areata (AA) and found deuruxolitinib higher doses (12 mg) and baricitinib (4 mg) showed promise in hair regrowth improvement, but further research must be done to confirm these results while more long-term effects are explored.
Scalp-cooling therapy (SCT) is a treatment that may help reduce hair loss in women with breast cancer who are experiencing chemotherapy-induced alopecia (CIA). A study found that many women who used SCT were satisfied with the results, but the treatment is expensive, making it necessary for more advocacy by health care professionals to make SCT accessible.
A case controlled study suggests a gene variant may offer some protection from frontal fibrosing alopecia (FFA), but only if there is no prior history of oral contraceptive pill use, which appears to increase the risk for carriers of this variant.
Platelet-rich plasma (PRP) treatment increased hair regrowth in patients with androgenetic alopecia (AGA) and may help rebalance the scalp microbiome, although the link between the microbiome changes and hair growth needs future investigations.
A study using a large Korean health database found that people with a rare hair loss disorder called primary cicatricial alopecia were more likely to also have additional health problems like diabetes and high blood pressure compared with people who had other hair loss conditions or no hair loss at all.
A study found scalp repair serum microneedle combined therapy with medication to improve hair growth outcomes for patients with moderate to severe androgenetic alopecia (AGA) and reduce the number of microneedling sessions necessary.
A genetic study suggests people with allergies and eczema are more likely to develop alopecia areata, an autoimmune disease that causes hair loss. Researchers believe this link may be due to similar immune system responses.
A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
A survey study found a strong association between severe alopecia areata (AA) and significant impairments in quality of life and mental wellbeing, highlighting the need for comprehensive treatment addressing both physical and emotional aspects of the disease.
Potential links between alopecia areata (AA) and hypothyroidism were observed among the study but the connection between androgenetic alopecia (AG) and hypothyroidism needs further investigation.
Studies show that laser-assisted drug delivery (LADD) improves hair growth in patients with alopecia. However, researchers are still looking at the best ways to compare LADD's effectiveness against other methods like microneedling.
Antibodies targeting the CXCL12 protein show potential to promote hair growth in conditions like androgenic alopecia (AGA) and alopecia areata (AA), offering hope for new treatment options.
Corticosteroids are the most common treatment for pediatric patients with alopecia areata (AA), but promising newer options like JAK inhibitors are emerging. This review highlights the importance of personalized treatment plans and maximizing response through combination therapies.
Red and near-infrared–emitting fabric clothing may improve symptoms of mild psoriasis, polymorphous light eruption (PMLE), and alopecia areata (AA), but further research with larger groups is needed due to limitations in the pilot study design.
Patients with alopecia areata (AA) often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. This study highlights the importance of understanding patient perception for better treatment and improved quality of life.
Research suggests tofacitinib effectively treats alopecia areata (AA), particularly when used early for severe cases. This offers promising evidence for doctors to consider when making treatment plans for patients.
Posters suggest deuruxolitinib, a medication targeting specific cellular pathways, effectively promotes hair regrowth in patients with moderate to severe alopecia areata (AA) and results in minimal adverse events.
Baricitinib and other oral JAK inhibitors show promise as effective treatments for moderate-to-severe alopecia areata (AA), with fewer adverse effects compared with traditional options.
A study in San Bernardino County found no increased risks of alopecia areata (AA) after the COVID-19 vaccination but suggests further research into potential geographic and gender-based factors.
A study found baricitinib to be safe and effective for treating severe alopecia areata (AA) but expressed the need for more long-term trials to support these findings.
An expert survey using the eDelphi method pinpointed disease duration, treatment response, and mental health as crucial factors in a new multidimensional tool known as Alopecia Areata Severity and Morbidity Index (ASAMI), underlining the importance of personalized treatments for future research incorporating patient perspectives.
Women with alopecia areata (AA), especially those with severe symptoms and lower income, face significant financial burden managing the condition.
A Japanese study of alopecia areata (AA) found misalignment between patient and doctor perceptions of severity, limiting treatment options, and leading to dissatisfaction and unmet needs.
